1. Schumacher GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, McDowell F, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis.
Ann N Y Acad Sci 1965;122:552-568.
2. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
Ann Neurol 1983;13:227-231.
3. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.
Ann Neurol 2001;50:121-127.
5. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
Lancet Neurol 2018;17:162-173.
6. Brownlee WJ, Swanton JK, Altmann DR, Ciccarelli O, Miller DH. Earlier and more frequent diagnosis of multiple sclerosis using the McDonald criteria.
J Neurol Neurosurg Psychiatry 2015;86:584-585.
7. Solomon AJ, Bourdette DN, Cross AH, Applebee A, Skidd PM, Howard DB, et al. The contemporary spectrum of multiple sclerosis misdiagnosis: a multicenter study.
Neurology 2016;87:1393-1399.
8. Kaisey M, Solomon AJ, Luu M, Giesser BS, Sicotte NL. Incidence of multiple sclerosis misdiagnosis in referrals to two academic centers.
Mult Scler Relat Disord 2019;30:51-56.
9. Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: progress and challenges.
Lancet 2017;389:1336-1346.
11. Adams CW, Poston RN, Buk SJ. Pathology, histochemistry and immunocytochemistry of lesions in acute multiple sclerosis.
J Neurol Sci 1989;92:291-306.
12. Liu S, Kullnat J, Bourdette D, Simon J, Kraemer DF, Murchison C, et al. Prevalence of brain magnetic resonance imaging meeting Barkhof and McDonald criteria for dissemination in space among headache patients.
Mult Scler 2013;19:1101-1105.
13. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration.
Lancet Neurol 2013;12:822-838.
15. Garg N, Reddel SW, Miller DH, Chataway J, Riminton DS, Barnett Y, et al. The corpus callosum in the diagnosis of multiple sclerosis and other CNS demyelinating and inflammatory diseases.
J Neurol Neurosurg Psychiatry 2015;86:1374-1382.
16. Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update.
Neurology 2015;84:1165-1173.
17. Wang KY, Chetta J, Bains P, Balzer A, Lincoln J, Uribe T, et al. Spectrum of MRI brain lesion patterns in neuromyelitis optica spectrum disorder: a pictorial review.
Br J Radiol 2018;91:20170690.
18. Bø L, Vedeler CA, Nyland HI, Trapp BD, Mørk SJ. Subpial demyelination in the cerebral cortex of multiple sclerosis patients.
J Neuropathol Exp Neurol 2003;62:723-732.
19. Sethi V, Muhlert N, Ron M, Golay X, Wheeler-Kingshott CA, Miller DH, et al. MS cortical lesions on DIR: not quite what they seem?
PLoS One 2013;8:e78879.
20. Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.
Lancet Neurol 2016;15:292-303.
21. Banks SA, Morris PP, Chen JJ, Pittock SJ, Sechi E, Kunchok A, et al. Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS.
J Neurol Neurosurg Psychiatry 2021;92:384-390.
22. Koçer N, Islak C, Siva A, Saip S, Akman C, Kantarci O, et al. CNS involvement in neuro-Behçet syndrome: an MR study.
AJNR Am J Neuroradiol 1999;20:1015-1024.
23. Lycklama G, Thompson A, Filippi M, Miller D, Polman C, Fazekas F, et al. Spinal-cord MRI in multiple sclerosis.
Lancet Neurol 2003;2:555-562.
24. Ciccarelli O, Cohen JA, Reingold SC, Weinshenker BG, International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders.
Lancet Neurol 2019;18:185-197.
25. Dubey D, Pittock SJ, Krecke KN, Morris PP, Sechi E, Zalewski NL, et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody.
JAMA Neurol 2019;76:301-309.
26. Geraldes R, Ciccarelli O, Barkhof F, De Stefano N, Enzinger C, Filippi M, et al. The current role of MRI in differentiating multiple sclerosis from its imaging mimics.
Nat Rev Neurol 2018;14:199-213.
27. Rovira À, Wattjes MP, Tintoré M, Tur C, Yousry TA, Sormani MP, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process.
Nat Rev Neurol 2015;11:471-482.
28. Charil A, Yousry TA, Rovaris M, Barkhof F, De Stefano N, Fazekas F, et al. MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation".
Lancet Neurol 2006;5:841-852.
30. Mistry N, Abdel-Fahim R, Samaraweera A, Mougin O, Tallantyre E, Tench C, et al. Imaging central veins in brain lesions with 3-T T2*-weighted magnetic resonance imaging differentiates multiple sclerosis from microangiopathic brain lesions.
Mult Scler 2016;22:1289-1296.
31. Sati P, Oh J, Constable RT, Evangelou N, Guttmann CR, Henry RG, et al. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative.
Nat Rev Neurol 2016;12:714-722.
32. Ontaneda D, Sati P, Raza P, Kilbane M, Gombos E, Alvarez E, et al. Central vein sign: a diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a prospective multicenter trial.
Neuroimage Clin 2021;32:102834.
33. Tallantyre EC, Dixon JE, Donaldson I, Owens T, Morgan PS, Morris PG, et al. Ultra-high-field imaging distinguishes MS lesions from asymptomatic white matter lesions.
Neurology 2011;76:534-539.
35. Sinnecker T, Clarke MA, Meier D, Enzinger C, Calabrese M, De Stefano N, et al. Evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis.
JAMA Neurol 2019;76:1446-1456.
36. Kaunzner UW, Kang Y, Zhang S, Morris E, Yao Y, Pandya S, et al. Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions.
Brain 2019;142:133-145.
37. Absinta M, Sati P, Fechner A, Schindler MK, Nair G, Reich DS. Identification of chronic active multiple sclerosis lesions on 3T MRI.
AJNR Am J Neuroradiol 2018;39:1233-1238.
39. Rovira À, Auger C. Beyond McDonald: updated perspectives on MRI diagnosis of multiple sclerosis.
Expert Rev Neurother 2021;21:895-911.